series-b
Stage
1
Investors
About
Sirius Therapeutics develops RNA interference (RNAi) therapeutics targeting cardiovascular and chronic diseases, advancing novel siRNA medicines to reduce significant cardiovascular risks.
Explore Sirius Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.